literature

HIV mutation literature information.

Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.

PMID: 35001501 2022 Journal of the International AIDS Society

Method: We excluded individuals with prior evidence of NNRTI-associated resistance mutations based on the IAS-USA HIV drug-resistance mutations list (2019) (V90I, A98G, L100I, K101E/H/P/Q/R/N, K103N/S, V106A/M/I, V108I, E138K/A/G/Q/R, V179D/F/L/T, Y181C/I/V, Y188L/C/H, G190A/S/E,H221Y, P225H, F227L/C/R,

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.

PMID: 34694877 2022 Antimicrobial agents and chemotherapy

Result: Integrase mutants with G118R or G118R plus E138K exhibited faster doluteg

Result: A subcluster of sequences containing K160T in addition to G118R, E138K, and R263K showed the greatest evolutionary distance.

Result: Clonal and population sequences at CVW from participant 3 had multiple evolving pathways with >=2 integrase substitutions, with separate clusters forming for sequences containing H51Y and G118R (bootstrap = 96%) and those containing G118R, E138K, and R263K (bootstrap = 90%).

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.

PMID: 34694878 2022 Antimicrobial agents and chemotherapy

Abstract: G118R reduced dolutegravir susceptibility and integrase replication capacity mor

Result: Additional integrase substitutions accumulated at weeks 136 and 168, with genotyping results of E138A/E/K/T, S147G/S, and R263K and E138T, S147G, and R263K, respectively.

Result: Four of 5 participants with G118R had 1 additional treatment-emergent INSTI-associated substitution of L74M, E138E/K, E92E/Q, or T66I, respectively.

Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.

PMID: 34871089 2022 Antimicrobial agents and chemotherapy

Method: Patients with previously documented HIV-2 infection, with active AIDS, and with documented genotypic evidence of >=1 NNRTI resistance-associated mutation (RAM) from a predefined list of the following NNR

Result: The most frequent treatment-emergent RPV RAM at the last post-baseline time point was E138K (5/15 patients [33.3%]).

Result: Three patients had both treatment-emergent RPV RAM E138K and NRTI RAM M184V at the last post-baseline time point with genotypic data.

Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.

PMID: 34897227 2022 Journal of acquired immune deficiency syndromes (1999)

Table: E138K/A

Discussion: In the 3 real-world cases, other INSTI-R substitutions were also noted, including L74I, E138K, S147G, and H51Y, along with M184V in RT.

Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine.

PMID: 34978890 2022 Antimicrobial agents and chemotherapy

Result: However, when E138K was introduced into either clone, EC50 values against rilpivirine were above the biological cutoff, with fold change values of 2.38 and 2.21 for the viruses with PR/RT genes from NL4-3 and 92UG307, respectively.

Result: Therefore, the known E138K and K101E mutations conferred EC50 fold change values consistent with in vitro resistance to rilpivirine equally across clones containing PR/RT genes from HIV-1 subtypes B and A1 (https://hivdb.stanford.edu/dr-summary/resistance-notes/NNRTI/).

Discussion: As the presence of E138K alone has been associated with decreased susceptibility to rilpivirine, the discrepancy observed between observations

Management of a human immunodeficiency virus case with discordant antiviral drug resistance profiles in cerebrospinal fluid compared with plasma: a case report.

PMID: 35164871 2022 Journal of medical case reports

Conclusion: The HIV-1 pol gene genotypic resistance analysis showed development of the NRTI M184V mutation, and NNRTI K103N and E138EK mutations in plasma, respectively.

Conclusion: The nonpolymorphic NNRTI K103N mutation causes high-level resistance to efavirenz (EFV), and E138K mutation causes potential low-level cross-resistance to EFV, which was discontinued together with 3TC.

High Level of Pre-Treatment HIV-1 Drug Resistance and Its Association with HLA Class I-Mediated Restriction in the Pumwani Sex Worker Cohort.

PMID: 35215866 2022 Viruses

Res

Result: For example, E138K, a well-known escape mutation, was first identified in participant ML874 (A*68:02+) in the blood sample collected in 1996, and this DRM was also detected in the samples collected in 2003 from the same participant.

Result: The HLA-DRM associations involving HLA alleles at >10% frequency in Kenya are A*68:02 with DRMs G190ES (p = 0.008), IN E138K (p = 0.042), C*17:01 with DRMs M46I (p = 0.018), and IN E138K (p = 0.021).

Could Long-Acting Cabotegravir-Rilpivirine Be the Future for All People Living with HIV? Response Based on Genotype Resistance Test from a Multicenter Italian Cohort.

PMID: 35207677 2022 Journal of personalized medicine

Method: Furthermore, we excluded people with the following mutations for NNRTI: L100I, K101E/H/NP/Q, E138A/G/K/Q/R, V179L, Y181C/F/G/I/S/V, Y188L, G190A/C/E/Q/S/T/V, H221Y, F227C/L, and M230L.

Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia.

PMID: 35458459 2022 Viruses

Result: In this study,19 substitutions conferring major resistance to DTG at 10 amino acid positions in the IN (T66A/I/K, E92G, G118R, E138K/A/T, G140S/A/C, Y143R/C/H, S147G, Q148H/R/K, N155H, and R263K) were assessed to explore the genetic barrier to DTG.

Result: No major DRMs known to be associated with DTG resistance (T66K, E92Q, G118R, E138K/A/T, G140S/A/C<

Browser Board

Co-occurred Entities

Filtrator